We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FOLD reported Q4 EPS of 10 cents, missing estimates, as revenues rose 24% Y/Y to $185.2M.
Amicus saw Galafold sales rise 14% and Pombiliti plus Opfolda jump 51% Y/Y at constant exchange rates.
BioMarin will acquire Amicus for $14.50 per share in a $4.8B cash deal set to close in Q2 2026.
Amicus Therapeutics (FOLD - Free Report) reported adjusted earnings of 10 cents per share for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 13 cents. The company had reported adjusted earnings of 9 cents per share in the year-ago quarter.
Revenues in the fourth quarter totaled $185.2 million, up 24% year over year on a reported basis and 20% at constant exchange rates (CER). The figure beat the Zacks Consensus Estimate of $180 million. The top line comprised sales of Galafold (migalastat), which is approved for Fabry disease, and the newly approved combo drug, Pombiliti + Opfolda.
Pombiliti + Opfolda, a two-component therapy, is approved for treating late-onset Pompe disease.
The top line increased year over year owing to higher revenues from Galafold and Pombiliti + Opfolda. Both Fabry and Pompe are rare diseases.
In the past six months, shares of Amicus have rallied 91.7% compared with the industry’s 22.8% rise.
Image Source: Zacks Investment Research
FOLD's Q4 Earnings in Detail
Galafold sales totaled $150.2 million, up 14% year over year at CER. Sales of the drug were driven by new patient starts, continued commercial execution in all markets and strong compliance.
Galafold sales missed the Zacks Consensus Estimate of $157 million.
Net product sales of Pombiliti + Opfolda were $35 million, up 51% year over year at CER. The reported figure slightly beat the Zacks Consensus Estimate of $34.8 million.
Adjusted operating expenses rose 17% to $114.2 million in the fourth quarter of 2025.
As of Dec. 31, 2025, Amicus had cash, cash equivalents and marketable securities worth $293.5 million compared with $263.8 million as of Sept. 30, 2025.
FOLD's Full-Year 2025 Results
For 2025, Amicus generated revenues of $634.2 million, reflecting a 17% increase year over year at CER.
For the same period, the company reported adjusted earnings of 31 cents per share compared with earnings of 24 cents per share reported in the year-ago period.
FOLD Set to be Acquired by BMRN
In December 2025, BioMarin Pharmaceutical (BMRN - Free Report) entered into a definitive agreement to acquire all outstanding shares of Amicus for $14.50 per share in cash, totaling $4.8 billion. The deal is expected to be closed in the second quarter of 2026 and is subject to customary closing conditions.
Post-completion of this acquisition, BioMarin will add Galafold and the combo drug Pombiliti to its commercial portfolio. BioMarin will also acquire exclusive U.S. rights to the late-stage pipeline drug DMX-200, which is being developed to treat a rare and fatal kidney disease called focal segmental glomerulosclerosis.
Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have increased from $3.72 to $4.00. HRMY shares have fallen 22.1% in the past six months.
Harmony Biosciences’ earnings beat estimates in two of the trailing four quarters and missed in the remaining two quarters, with the average earnings surprise being 7.20%.
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL shares have rallied 42% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
Key Takeaways
Amicus Therapeutics (FOLD - Free Report) reported adjusted earnings of 10 cents per share for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 13 cents. The company had reported adjusted earnings of 9 cents per share in the year-ago quarter.
Revenues in the fourth quarter totaled $185.2 million, up 24% year over year on a reported basis and 20% at constant exchange rates (CER). The figure beat the Zacks Consensus Estimate of $180 million. The top line comprised sales of Galafold (migalastat), which is approved for Fabry disease, and the newly approved combo drug, Pombiliti + Opfolda.
Pombiliti + Opfolda, a two-component therapy, is approved for treating late-onset Pompe disease.
The top line increased year over year owing to higher revenues from Galafold and Pombiliti + Opfolda. Both Fabry and Pompe are rare diseases.
In the past six months, shares of Amicus have rallied 91.7% compared with the industry’s 22.8% rise.
Image Source: Zacks Investment Research
FOLD's Q4 Earnings in Detail
Galafold sales totaled $150.2 million, up 14% year over year at CER. Sales of the drug were driven by new patient starts, continued commercial execution in all markets and strong compliance.
Galafold sales missed the Zacks Consensus Estimate of $157 million.
Net product sales of Pombiliti + Opfolda were $35 million, up 51% year over year at CER. The reported figure slightly beat the Zacks Consensus Estimate of $34.8 million.
Adjusted operating expenses rose 17% to $114.2 million in the fourth quarter of 2025.
As of Dec. 31, 2025, Amicus had cash, cash equivalents and marketable securities worth $293.5 million compared with $263.8 million as of Sept. 30, 2025.
FOLD's Full-Year 2025 Results
For 2025, Amicus generated revenues of $634.2 million, reflecting a 17% increase year over year at CER.
For the same period, the company reported adjusted earnings of 31 cents per share compared with earnings of 24 cents per share reported in the year-ago period.
FOLD Set to be Acquired by BMRN
In December 2025, BioMarin Pharmaceutical (BMRN - Free Report) entered into a definitive agreement to acquire all outstanding shares of Amicus for $14.50 per share in cash, totaling $4.8 billion. The deal is expected to be closed in the second quarter of 2026 and is subject to customary closing conditions.
Post-completion of this acquisition, BioMarin will add Galafold and the combo drug Pombiliti to its commercial portfolio. BioMarin will also acquire exclusive U.S. rights to the late-stage pipeline drug DMX-200, which is being developed to treat a rare and fatal kidney disease called focal segmental glomerulosclerosis.
Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise
Amicus Therapeutics, Inc. price-consensus-eps-surprise-chart | Amicus Therapeutics, Inc. Quote
FOLD's Zacks Rank & Stocks to Consider
Amicus currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) and Castle Biosciences (CSTL - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have increased from $3.72 to $4.00. HRMY shares have fallen 22.1% in the past six months.
Harmony Biosciences’ earnings beat estimates in two of the trailing four quarters and missed in the remaining two quarters, with the average earnings surprise being 7.20%.
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL shares have rallied 42% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.